World

Zelensky welcomes increased weapons deliveries

Nov 05, 2024

Kiev [Ukraine], November 5: Ukrainian President Volodymyr Zelensky highlighted increased arms deliveries from Western allies at a meeting with leading military figures on Monday.
"The results regarding deliveries for artillery have improved," he said in a Telegram message. This means that Ukraine's partners have moved closer to the pledges they have made, he said.
Last Wednesday, Zelensky complained that his country had only received around 10% of the aid approved by the US Congress. The topic of expanding Ukrainian drone production was also raised, particularly with regard to long-range drones. Manufacturers are to receive three- to five-year contracts, in a bid to give producers a perspective for development and investment.
Ukraine has been defending itself against the Russian invasion with Western help for more than two and a half years.
Kiev relies heavily on Western backing, which is a key issue ahead of the US presidential elections on Tuesday, as the candidates differ widely in their views on Ukraine. While Democratic candidate Kamala Harris is likely to continue Washington's current support for Kiev, former president Donald Trump has long criticized US spending on Ukraine. (DPA)
Source: Qatar Tribune

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025